OS Therapies (NYSEAMERICAN:OSTX) Lowered to “Strong Sell” Rating by Zacks Research

Zacks Research downgraded shares of OS Therapies (NYSEAMERICAN:OSTX) from a hold rating to a strong sell rating in a research note released on Wednesday,Zacks.com reports.

Separately, D. Boral Capital reaffirmed a “buy” rating and issued a $20.00 target price on shares of OS Therapies in a report on Thursday, April 30th. Two research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and an average price target of $18.50.

OS Therapies Price Performance

Shares of NYSEAMERICAN OSTX opened at $1.70 on Wednesday. OS Therapies has a 1 year low of $1.15 and a 1 year high of $2.57. The stock has a market cap of $67.20 million, a P/E ratio of -1.72 and a beta of -1.34. The firm has a 50-day moving average of $1.47 and a 200 day moving average of $1.55.

OS Therapies (NYSEAMERICAN:OSTX) last issued its earnings results on Tuesday, March 31st. The company reported ($0.41) earnings per share (EPS) for the quarter. Research analysts expect that OS Therapies will post -0.54 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the company. State Street Corp raised its holdings in OS Therapies by 16.3% in the fourth quarter. State Street Corp now owns 58,500 shares of the company’s stock worth $82,000 after buying an additional 8,200 shares during the last quarter. Jane Street Group LLC purchased a new position in OS Therapies in the fourth quarter worth about $39,000. Geode Capital Management LLC raised its holdings in OS Therapies by 31.1% in the fourth quarter. Geode Capital Management LLC now owns 246,038 shares of the company’s stock worth $344,000 after buying an additional 58,350 shares during the last quarter. Susquehanna International Group LLP bought a new stake in shares of OS Therapies in the third quarter worth approximately $29,000. Finally, Mercer Global Advisors Inc. ADV bought a new stake in shares of OS Therapies in the third quarter worth approximately $40,000.

About OS Therapies

OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. OS Therapies Incorporated was incorporated in 2018 and is based in Rockville, Maryland.